Creating new medications for weight loss and blood sugar control
Development of Anorexigenic and Glucoregulatory Chimeric Peptides
This project is developing new combination medications to help people with obesity and adult-onset diabetes manage their weight and blood sugar more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11172625 on NIH RePORTER |
What this research studies
Current treatments for obesity often don't provide lasting results or reverse the disease. This project believes that successful treatments need to target several related pathways in the body that control energy balance. Researchers are creating a new type of medication that combines the effects of three different signals in the body (GLP-1R, Y1-R, and Y2-R) to reduce appetite, improve insulin production, and lower glucagon. Early studies in animals have shown promising results, leading to significant weight loss and reduced food intake without common side effects like nausea.
Who could benefit from this research
Good fit: Ideal candidates for future studies would be adults aged 21 and older living with obesity and adult-onset diabetes.
Not a fit: Patients without obesity or adult-onset diabetes, or those under 21, would not directly benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this new medication could offer a more effective and lasting treatment option for obesity and adult-onset diabetes, potentially leading to greater weight loss and better blood sugar control than current therapies.
How similar studies have performed: While single-target medications like GLP-1R agonists have shown some success, this approach is novel in combining three targets to achieve potentially superior effects.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Roth, Christian Ludwig — Seattle Children's Hospital
- Study coordinator: Roth, Christian Ludwig
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.